Last reviewed · How we verify
RZV
RZV is a recombinant zoster vaccine that stimulates the immune system to prevent herpes zoster (shingles) infection.
RZV is a recombinant zoster vaccine that stimulates the immune system to prevent herpes zoster (shingles) infection. Used for Prevention of herpes zoster (shingles) in adults aged 50 years and older, Prevention of herpes zoster in immunocompromised adults aged 18 years and older.
At a glance
| Generic name | RZV |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Recombinant subunit vaccine |
| Target | Varicella-zoster virus glycoprotein E (gE) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
RZV contains recombinant varicella-zoster virus (VZV) glycoprotein E antigen combined with an AS01B adjuvant system that enhances immune response. The vaccine works by priming both cellular and humoral immunity against VZV, reducing the risk of herpes zoster reactivation and post-herpetic neuralgia in vaccinated individuals.
Approved indications
- Prevention of herpes zoster (shingles) in adults aged 50 years and older
- Prevention of herpes zoster in immunocompromised adults aged 18 years and older
Common side effects
- Myalgia
- Fatigue
- Headache
- Injection site pain
- Injection site erythema
- Injection site swelling
- Fever
Key clinical trials
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators (PHASE4)
- Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients
- Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation (PHASE2)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases (PHASE4)
- A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults (PHASE3)
- Immune Response of Shingrix Vaccine in People Living With HIV (> 50 y.o.) Compared to Age-matched Controls (PHASE4)
- VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RZV CI brief — competitive landscape report
- RZV updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI